• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Ticarcillin-clavulanic acid pharmacokinetics in preterm neonates with presumed sepsis.替卡西林-克拉维酸在疑似败血症早产儿中的药代动力学。
Antimicrob Agents Chemother. 1994 Sep;38(9):2024-8. doi: 10.1128/AAC.38.9.2024.
2
Pharmacokinetics of ticarcillin and clavulanic acid given in combination to adult horses by intravenous and intramuscular routes.成年马静脉注射和肌肉注射联用替卡西林和克拉维酸的药代动力学
J Vet Pharmacol Ther. 1988 Mar;11(1):103-8. doi: 10.1111/j.1365-2885.1988.tb00102.x.
3
Pharmacokinetics of intravenously and intramuscularly administered ticarcillin and clavulanic acid in foals.静脉注射和肌肉注射替卡西林和克拉维酸在幼驹体内的药代动力学。
Am J Vet Res. 1988 Jan;49(1):23-6.
4
Rational prescribing of extended-spectrum penicillin beta-lactamase inhibitor combinations: focus on ticarcillin/clavulanic acid.广谱青霉素β-内酰胺酶抑制剂联合制剂的合理处方:聚焦替卡西林/克拉维酸
Ann Pharmacother. 1998 Jan;32(1):S17-21. doi: 10.1177/106002809803200105.
5
Pharmacokinetic-based ticarcillin/clavulanic acid dose recommendations for infants and children.基于药代动力学的替卡西林/克拉维酸用于婴幼儿及儿童的剂量推荐
J Clin Pharmacol. 1995 Jul;35(7):658-65. doi: 10.1002/j.1552-4604.1995.tb04105.x.
6
Pharmacokinetics and bacteriological efficacy of ticarcillin-clavulanic acid (timentin) in experimental Escherichia coli K-1 and Haemophilus influenzae type b meningitis.替卡西林-克拉维酸(特美汀)在实验性大肠杆菌K-1和b型流感嗜血杆菌脑膜炎中的药代动力学及细菌学疗效
Antimicrob Agents Chemother. 1987 Sep;31(9):1296-300. doi: 10.1128/AAC.31.9.1296.
7
Penetration of amoxycillin, ticarcillin and clavulanic acid into lymph after intravenous infusion in rabbits to simulate human serum pharmacokinetics.静脉输注阿莫西林、替卡西林和克拉维酸后在兔体内的渗透情况,以模拟人体血清药代动力学。
J Antimicrob Chemother. 1990 Nov;26(5):695-704. doi: 10.1093/jac/26.5.695.
8
The pharmacokinetics of ticarcillin/clavulanate acid in neonates.替卡西林/克拉维酸在新生儿中的药代动力学。
J Antimicrob Chemother. 1989 Nov;24 Suppl B:111-20. doi: 10.1093/jac/24.suppl_b.111.
9
Ticarcillin/clavulanic acid pharmacokinetics in children and young adults with cystic fibrosis.替卡西林/克拉维酸在患有囊性纤维化的儿童和年轻成人中的药代动力学。
J Pediatr. 1985 Jun;106(6):1001-7. doi: 10.1016/s0022-3476(85)80258-4.
10
Ex vivo pharmacodynamic study of piperacillin alone and in combination with tazobactam, compared with ticarcillin plus clavulanic acid.单独使用哌拉西林以及与他唑巴坦联合使用的体外药效学研究,与替卡西林加克拉维酸的比较。
Antimicrob Agents Chemother. 1993 Sep;37(9):1860-8. doi: 10.1128/AAC.37.9.1860.

引用本文的文献

1
Optimal use of β-lactams in neonates: machine learning-based clinical decision support system.新生儿β-内酰胺类药物的最佳使用:基于机器学习的临床决策支持系统。
EBioMedicine. 2024 Jul;105:105221. doi: 10.1016/j.ebiom.2024.105221. Epub 2024 Jun 24.
2
Pharmacokinetics of Clavulanic Acid in the Pediatric Population: A Systematic Literature Review.儿童人群中克拉维酸的药代动力学:系统文献回顾。
Clin Pharmacokinet. 2022 May;61(5):637-653. doi: 10.1007/s40262-022-01116-3. Epub 2022 Mar 31.
3
Pharmacokinetics of Commonly Used Medications in Children Receiving Continuous Renal Replacement Therapy: A Systematic Review of Current Literature.儿童连续肾脏替代治疗中常用药物的药代动力学:当前文献的系统评价。
Clin Pharmacokinet. 2022 Feb;61(2):189-229. doi: 10.1007/s40262-021-01085-z. Epub 2021 Nov 30.
4
Pharmacokinetics of ticarcillin-clavulanate in premature infants.早产儿替卡西林-克拉维酸的药代动力学。
Br J Clin Pharmacol. 2019 May;85(5):1021-1027. doi: 10.1111/bcp.13882. Epub 2019 Mar 6.
5
Clinical Pharmacokinetics of Penicillins, Cephalosporins and Aminoglycosides in the Neonate: A Review.新生儿期青霉素类、头孢菌素类和氨基糖苷类药物的临床药代动力学:综述
Pharmaceuticals (Basel). 2010 Aug 12;3(8):2568-2591. doi: 10.3390/ph3082568.
6
Clinical pharmacokinetics of penicillins in the neonate: a review of the literature.新生儿青霉素类药物的临床药代动力学:文献综述
Eur J Clin Pharmacol. 2009 Feb;65(2):191-8. doi: 10.1007/s00228-008-0562-y. Epub 2008 Sep 23.
7
Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates.阿贝卡星、万古霉素和帕尼培南在新生儿中的群体药代动力学。
Antimicrob Agents Chemother. 2004 Apr;48(4):1159-67. doi: 10.1128/AAC.48.4.1159-1167.2004.
8
Antibiotics in neonatal infections: a review.新生儿感染中的抗生素:综述
Drugs. 1999 Sep;58(3):405-27. doi: 10.2165/00003495-199958030-00003.

本文引用的文献

1
Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin.静脉注射环丙沙星群体药代动力学模型及最佳采样策略的建立
Antimicrob Agents Chemother. 1993 May;37(5):1065-72. doi: 10.1128/AAC.37.5.1065.
2
Kinetic interactions of tazobactam with beta-lactamases from all major structural classes.他唑巴坦与所有主要结构类型的β-内酰胺酶的动力学相互作用。
Antimicrob Agents Chemother. 1993 Apr;37(4):851-8. doi: 10.1128/AAC.37.4.851.
3
Optimal sampling times for pharmacokinetic experiments.药代动力学实验的最佳采样时间。
J Pharmacokinet Biopharm. 1981 Dec;9(6):739-56. doi: 10.1007/BF01070904.
4
Pharmacokinetics and drug distribution during postnatal development.出生后发育过程中的药代动力学和药物分布。
Pharmacol Ther. 1982;18(2):159-97. doi: 10.1016/0163-7258(82)90066-3.
5
Antibacterial activity of ticarcillin in the presence of clavulanate potassium.替卡西林在克拉维酸钾存在下的抗菌活性。
Am J Med. 1985 Nov 29;79(5B):13-24. doi: 10.1016/0002-9343(85)90124-x.
6
Bioavailability and pharmacokinetics of clavulanic acid in healthy subjects.
Int J Clin Pharmacol Ther Toxicol. 1985 Feb;23(2):70-3.
7
Pharmacokinetics of parenteral ticarcillin formulated with clavulanic acid: Timentin.与克拉维酸联合使用的注射用替卡西林的药代动力学:特美汀
Int J Clin Pharmacol Ther Toxicol. 1986 Mar;24(3):123-9.
8
The prophylactic use of ticarcillin/clavulanate in the neonate.
J Antimicrob Chemother. 1987 Jan;19(1):113-8. doi: 10.1093/jac/19.1.113.
9
An evaluation of optimal sampling strategy and adaptive study design.
Clin Pharmacol Ther. 1988 Aug;44(2):232-8. doi: 10.1038/clpt.1988.142.
10
The pharmacokinetics of ticarcillin/clavulanate acid in neonates.替卡西林/克拉维酸在新生儿中的药代动力学。
J Antimicrob Chemother. 1989 Nov;24 Suppl B:111-20. doi: 10.1093/jac/24.suppl_b.111.

替卡西林-克拉维酸在疑似败血症早产儿中的药代动力学。

Ticarcillin-clavulanic acid pharmacokinetics in preterm neonates with presumed sepsis.

作者信息

Burstein A H, Wyble L E, Gal P, Diaz P R, Ransom J L, Carlos R Q, Forrest A

机构信息

Division of Neuropharmacology, Dent Neurologic Institute, Millard Fillmore Hospital, Buffalo, New York 14209.

出版信息

Antimicrob Agents Chemother. 1994 Sep;38(9):2024-8. doi: 10.1128/AAC.38.9.2024.

DOI:10.1128/AAC.38.9.2024
PMID:7811013
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC284678/
Abstract

The objective of the reported study was to characterize the pharmacokinetics of ticarcillin and clavulanic acid in premature low-birth-weight (less than 2,200 g) neonates with presumed sepsis. Eleven infants received 12 courses of ticarcillin-clavulanic acid at 75 mg/kg of body weight intravenously every 12 h. Blood samples were collected at 0.5, 1.5, 4, and 8 h following the infusion of the initial dose. The concentrations of ticarcillin and clavulanic acid were determined by a microbiologic assay. Median (interpatient coefficients of variation) values for the volume of the central compartment, total steady-state volume, distributional clearance, total clearance, and terminal elimination half-life for ticarcillin were 0.030 liter/kg (21%), 0.26 liter/kg (48%), 0.41 liter/h/kg (47%), 0.047 liter/h/kg (47%), and 4.2 h (45%), respectively. For clavulanic acid the parameters were 0.28 liter/kg (32%), 0.36 liter/kg (34%), 11 liters/h/kg (36%), 0.12 liters/h/kg (72%), and 1.95 h (40%), respectively. Our results suggest that the current dosing recommendations of 75 mg/kg every 12 h risk subtherapeutic clavulanic acid concentrations and that 50 mg/kg every 6 h is a more rational dosing strategy.

摘要

该报告研究的目的是描述替卡西林和克拉维酸在疑似败血症的早产低体重(小于2200克)新生儿中的药代动力学特征。11名婴儿接受了12个疗程的替卡西林-克拉维酸治疗,剂量为每12小时静脉注射75毫克/千克体重。在输注初始剂量后的0.5、1.5、4和8小时采集血样。替卡西林和克拉维酸的浓度通过微生物测定法测定。替卡西林中央室容积、总稳态容积、分布清除率、总清除率和末端消除半衰期的中位数(患者间变异系数)值分别为0.030升/千克(21%)、0.26升/千克(48%)、0.41升/小时/千克(47%)、0.047升/小时/千克(47%)和4.2小时(45%)。对于克拉维酸,这些参数分别为0.28升/千克(32%)、0.36升/千克(34%)、11升/小时/千克(36%)、0.12升/小时/千克(72%)和1.95小时(40%)。我们的结果表明,目前每12小时75毫克/千克的给药建议有导致克拉维酸浓度低于治疗水平的风险,每6小时50毫克/千克是一种更合理的给药策略。